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Abstract
Background—Detection of hepatic metastases during EUS is an important component of tumor 
staging.
Objective—To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic 
masses and derive and validate criteria to help distinguish between benign and malignant hepatic 
masses.
Design—Retrospective study, survey.
Setting—Single, tertiary-care referral center.
Patients—Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic 
masses over a 12-year period.
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Interventions—EUS-FNA of solid hepatic masses.
Main Outcome Measurements—Masses were deemed benign or malignant according to 
predetermined criteria. EUS images from 200 patients were used to create derivation and 
validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert 
endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in 
the derivation cohort. These data were used to derive an EUS scoring system that was then 
validated by using the validation cohort by the expert endosonographer with the highest diagnostic 
accuracy.
Results—A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver 
agreement regarding the initial endosonographic features among the expert endosonographers was 
fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring 
system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic 
masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 
0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined 
positive predictive value of both cohorts was 88%.
Limitations—Single center, retrospective, only one expert endosonographer deriving and 
validating the EUS criteria.
Conclusion—An EUS scoring system was developed that helps distinguish benign from 
malignant hepatic masses. Further study is required to determine the impact of these EUS criteria 
among endosonographers of all experience.
Imaging of the liver is an essential component of cancer staging because the liver is an 
important site of distant metastases for most tumor types.1,2 The resulting impact on 
prognosis, selection of therapy, and patient outcome is substantially altered in the majority 
of patients with hepatic metastases.3,4 For most cancers, the finding of hepatic metastasis 
indicates a noncurative status and poor prognosis with shortened survival.3–7 The liver is 
most often assessed for metastases by CT or magnetic resonance imaging (MRI). However, 
the accuracy of these imaging modalities for detecting hepatic masses and distinguishing 
benign from malignant masses is limited.8–10 Given the impact on patient care and outcome, 
tissue confirmation of hepatic metastasis often is indicated.
Traditionally, and in many centers even today, percutaneous hepatic biopsy is preferred 
because of ease of access, reduced cost relative to EUS, and the belief that the liver cannot 
be well-examined or safely accessed for EUS-guided FNA (EUS-FNA). There are limited 
data assessing the capability of EUS for use in identifying and safely doing biopsies of 
hepatic masses and in understanding EUS features that discriminate benign from malignant 
hepatic masses.
The aim of this study was to derive and validate EUS criteria that can distinguish between 
benign and malignant solid hepatic masses and to determine the interobserver agreement 
(IOA) of these EUS features among an internationally recognized group of highly skilled 
endosonographers. Furthermore, we sought to examine our institutional experience with 
EUS-FNA of solid hepatic masses and compare EUS detection with noninvasive imaging 
methods.
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METHODS
Patient selection
A prospectively maintained Mayo Clinic, Rochester, EUS database was reviewed to identify 
consecutive patients who underwent EUS-FNA of hepatic masses from January 1, 2000 
through March 30, 2012. The Institutional Review Board granted study approval. Data 
pertaining to the clinical presentation, noninvasive imaging features, EUS findings, 
pathology interpretations, treatment, and patient outcomes were collected. Electronically 
stored images from all EUS examinations were reviewed by M.J.L, who was blinded to all 
details of patient medical records and did not know which patients had benign or malignant 
hepatic lesions. Images that corresponded to the sampled hepatic masses, as verified by the 
presence of an image showing an FNA needle within the mass and/or having identical 
dimensions to that described in the procedure note, were identified. Patients were excluded 
whenever the mass from which the biopsy specimen was obtained could not be confirmed 
and/or the available images were of insufficient quality.
DIAGNOSTIC CRITERION STANDARD
FNA interpretations were compared with a strict diagnostic criterion standard. The hepatic 
mass was considered malignant if within 3 months of the index EUS examination either of 
the following were documented: (1) Cytology and/or histology obtained from the mass was 
interpreted as positive for malignancy, based on material obtained via EUS, percutaneous or 
surgical routes, or autopsy. (2) There was a new or enlarging radiographic (CT or MRI) 
hepatic mass that the reporting radiologist interpreted as clearly indicative of metastasis.
The hepatic mass was considered benign when both of the following were present: EUS-
FNA was interpreted as benign or negative for malignancy, and any one of the following was 
true: (1) No imaging before EUS, but radiographic (CT or MRI) imaging 6 months or more 
after the index EUS-FNA examination was interpreted as classic for a benign hepatic mass 
or showing no lesion. (2) Radiographic (CT or MRI) imaging before EUS showed an 
indeterminate hepatic mass, which on repeat radiographic imaging at 6 months or later had 
resolved or was seen but without enlargement, was benign appearing, and imaging showed 
no new hepatic masses. (3) The patient was alive, without clinical evidence of malignancy, at 
least 24 months after the index EUS examination.
When the findings did not satisfy the criteria for a malignant or benign hepatic mass, the 
results were deemed indeterminate, and the case was excluded from subsequent analysis. 
The EUS-FNA interpretations were compared with the strict diagnostic criterion standard to 
determine the number of true positive (TP), false positive, true negative (TN), or false 
negative results. Selection of EUS cases for the subsequent interobserver study mandated 
both a verifiable and representative EUS image of the sampled mass and a TP or TN FNA 
cytology result. The masses with predominantly cystic components were excluded. The 
remaining images were deidentified and separated into 2 groups consisting of 100 cases each 
that were matched with regard to the primary tumor site and the percentage of TP and TN 
results. (Appendix 1, available online at www.giejournal.org).
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INTEROBSERVER STUDY OF THE INITIAL ENDOSONOGRAPHIC 
CHARACTERIZATION
Deidentified EUS images of the first set of 100 hepatic mass images (derivation cohort) were 
incorporated into a research electronic data capture (REDCap) survey. REDCap is a secure, 
Web-based application designed to support data capture for research studies.11
The first review of the derivation cohort involved completion of the REDCap survey by 10 
expert endosonographers who were blinded to all clinical and cytopathology information, 
each using a unique password. In addition to rating 15 EUS features of each lesion, the 
reviewers provided their opinions as to whether the mass was benign or malignant. The 15 
questions addressed potentially predictive features that were chosen based on their use when 
other structures at EUS were being described and based on the clinical experience of 
endosonographers and sonographers within our institution doing noninvasive procedures.
Each expert endosonographer had performed a lifetime median of 10,000 (range 2000–
40,000) upper GI EUS examinations and a median of 875 (range 400–2200) examinations 
over the previous year.
Derivation and validation of EUS criteria
A summary of the derivation and validation process is found in Figure 1. The IOA for the 15 
initial endosonographic characteristics was deemed to be inadequate to derive EUS criteria 
that helped to distinguish benign from malignant hepatic masses. Therefore, focus shifted to 
create criteria that were more comprehensive, succinct, and generalizable.
For second review of the derivation cohort, the expert endosonographer (M.J.L) who had the 
highest diagnostic accuracy was unblinded to the criterion standard diagnosis of each hepatic 
mass image within the cohort. By using the responses to the questions pertaining to the 15 
initial endosonographic characteristics of each image from the other 9 experts, he 
reevaluated the 100 masses in the derivation cohort, attempting to define more concise EUS 
features. This repeat review allowed derivation of new EUS features (as highlighted in 
Appendices 2 and 3, available online at www.giejournal.org) that combined 5 initial 
endosonographic characteristics with 2 new characteristics that distinguished benign from 
malignant hepatic masses. Logistic regression analysis was performed on these new EUS 
features to determine the strength of the association between each feature and malignant 
versus benign masses, based on the criterion standard diagnosis. Those features significantly 
associated with outcome (odds ratio [OR] >1 for malignant masses and <1 for benign 
masses, with 95% confidence intervals not crossing 1) were included in deriving the EUS 
criteria. These OR estimates were then converted into a point system based on the strength 
of association with the criterion standard diagnosis, allowing development of EUS criteria 
that predicted malignant masses. By using the point system, a score of ≥ 3 points was 
deemed to be the most predictive of malignancy. The derivation cohort was reviewed for a 
third time by M.J.L to determine the area under the receiver operating characteristic curve 
(AUC) of this derived EUS criteria.
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To validate these criteria, M.J.L then applied the derived predictive EUS features to the 
second set of 100 masses (validation cohort). During the validation process, the 
endosonographer was blinded to all clinical and cytopathology data. The performance of the 
derived EUS criteria was compared between the derivation and validation cohorts by using 
the AUC, sensitivity, specificity, positive predictive value, and negative predictive value. The 
Hosmer-Lemeshow test was used to assess the goodness-of-fit of the predictive model.
Statistical analysis
Statistical analysis was performed by using either SAS version 9.2 software (SAS Institute, 
Cary, NC) or JMP software (version 9.0.1, SAS institute Inc). Continuous variables are 
reported as either a mean and standard deviation (SD) or median and range. Means were 
reported unless the data were nonparametric. The t test was used to analyze continuous 
variables, and a Pearson chi-square analysis was used for categorical variables. Statistical 
significance was set at a 2-sided P value of .05 or less. A multiple-rater kappa statistic was 
used to determine the IOA for each of these characteristics. A kappa of 0.21 to 0.4 was 
considered fair, 0.41 to 0.6 moderate, and 0.61 to 0.8 substantial. The derivation and 
validation of the EUS criteria were described earlier.
RESULTS
Patient characteristics: all patients
A total of 336 patients (mean [± SD] age 64 ± 12 years; 60% male, 96% white) who 
underwent EUS-FNA of a solid hepatic mass in the 12-year period were identified. The 
majority (87%) underwent EUS to evaluate malignancy including pancreatic 
adenocarcinoma (n = 154, 53%), esophageal adenocarcinoma (n = 40, 14%), neuroendocrine 
tumor (n = 30, 10%), biliary and/or gallbladder cancer (n = 17, 6%), gastric cancer (n = 13, 
5%), colorectal adenocarcinoma (n = 5, 2%), hepatocellular carcinoma (n = 4, 1%), 
ampullary adenocarcinoma (n = 4, 1%), adenocarcinoma of unknown primary site (n = 4, 
1%), and other (n = 17, 7%; including genitourinary cancer, breast or ovarian cancer, 
melanoma, lung cancer, lymphoma, thyroid cancer, and GI stromal tumor). The indications 
for EUS included assessment and/or staging of a pancreatic mass in 211 patients (63%), 
hepatic mass and esophageal mass in 41 patients each (12% each), gastric mass in 14 
patients (4%), other cancer staging in 19 patients (6%), and other indications in 10 patients 
(n = 3%; including gallbladder mass, mesenteric mass, mediastinal lymphadenopathy, and 
recurrent pancreatitis).
Accuracy, reliability, and safety of EUS-FNA
During EUS, a mean (± SD) of 3 ± 2 hepatic masses were seen in the left lobe (89.3%), right 
lobe (2.5%), both lobes (5.7%), caudate lobe (0.7%), and hilum (1.8%). The median long 
axis length was 9 mm (range 1–100 mm), with 22.2% of the lesions being ≤5 mm. A mean 
of 3.4 ± 1.8 FNA passes were obtained from sampled hepatic masses, of which 95.8% were 
interpreted as displaying adequate cellularity. Of these, 170 (52.8%) had negative results, 12 
(3.7%) had atypical results, 17 (5.3%) had suspicious results, and 123 (38.2%) had results 
positive for malignancy.
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The majority of patients (78.5%) had a CT scan during the evaluation at a median of 6 days 
before EUS (range 92 days before EUS to 28 days after EUS). CT detected a hepatic mass in 
the left hepatic lobe of 51% of patients seen by EUS. The masses detected by CT were 
significantly larger (mean [± SD] 15.3 mm ± 13.1 mm) than those detected by EUS alone 
(mean 8.8 mm ± 6.2 mm; P < .001) and more often had results positive for malignancy by 
EUS-FNA than those not detected by CT (56.5% vs 20.7%, respectively; P < .001). TUS 
was performed in 16.7% of patients at a mean of 2.5 days before EUS (range 30 days before 
EUS to 22 days after EUS). Similarly, larger lesions were more commonly detected by TUS 
(mean 16.8 mm ± 14.4 mm vs 7.4 ± 5.3 mm in those detected and not detected; P = .13). 
Although 30.3% of the masses seen by TUS were positive for malignancy by EUS-FNA, 
compared with 4.6% of those not seen, this did not reach statistical significance.
When we used the definitions, thresholds, and grading of adverse events advocated by the 
American Society for Gastrointestinal Endoscopy, serious adverse events requiring 
hospitalization were reported in 10 patients (2.9%). They included worsening abdominal 
pain or nausea (n = 5), acute pancreatitis (n = 2), duodenal perforation (n = 2), and atrial 
fibrillation with rapid ventricular response (n = 1).12 Of the 5 patients with abdominal pain 
or nausea, 1 patient also underwent an EUS-guided, antegrade, across the anastomosis, stent 
placement across a strictured pancreaticoduodenostomy, and 1 patient underwent an ERCP 
and sphincterotomy with biliary stent placement for a malignant stricture, the same day as 
the index EUS-FNA. Patients spent a median of 1 day (range 1–5 days) in the hospital, with 
resolution of symptoms by use of conservative medical management. Duodenal perforations 
occurred in 2 patients with pancreatic cancer, both requiring surgical closure.
PATIENT CHARACTERISTICS: 200 PATIENTS WITH CRITERION STANDARD 
DIAGNOSIS AND EUS IMAGES
A diagnostic criterion standard was established in 275 patients (81.8%). Among these 
patients, representative EUS images of the hepatic mass from which biopsy was obtained 
were available in 228 patients, with 116 (50.9%) and 97 (42.7%) having a TP and TN result, 
respectively. Those patients with masses that were predominantly cystic were excluded. The 
remaining patients were divided into the derivation and validation cohorts, matched by their 
hepatic EUS-FNA cytology results (positive vs non-positive for malignancy) and underlying 
indication for EUS (adenocarcinoma vs non-adenocarcinoma and location of primary tumor) 
(Appendix 1, available online at www.giejournal.org).
IOA for initial endosonographic characteristics
The mean (± SD) accuracy of the diagnostic impression of the 10 experts, based on the 
derivation cohort of EUS images of hepatic masses, was 73.2% ± 5.55; range 68% to 88%; 
kappa 0.45. There was no statistical difference in the mean diagnostic accuracy between the 
48 adenocarcinoma lesions and 52 non-adenocarcinomas or benign lesions (68.7% ± 28.4% 
for adenocarcinoma and 74% ± 28.1% for non-adenocarcinomas; P = .35).
Overall, the IOA for the 15 initial endosonographic characteristics was fair, with a mean (± 
SD) kappa statistic of 0.39 ± 0.11 (Table 1). The IOA remained fair even when we focused 
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only on benign lesions (mean 0.32 ± 0.18), malignant lesions (mean 0.34 ± 0.11), 
adenocarcinomas (mean 0.34 ± 0.12), and non-adenocarcinoma tumors (mean 0.32 ± 0.13) 
and when we considered only the 4 endosonographers with the highest diagnostic accuracy 
(mean 0.33 ± 0.12). The kappa statistic was fair or moderate for 8 (53%) and 6 (40%) 
features, respectively. Only 1 feature (7%, mass echogenicity) provided a substantial kappa 
statistic.
Derivation and validation of EUS criteria
EUS criteria were derived to distinguish benign from malignant hepatic masses, based on the 
answers from the 10 expert endosonographers regarding the 15 endosonographic features 
and unblinded repeat review of the derivation cohort. The univariate OR of each EUS 
feature, reflecting its strength of association with a malignant hepatic lesion, is presented in 
Table 2. Detailed definitions of these features and guidance for their use are provided in 
Appendices 2 and 3, available online at www.giejournal.org. In order to develop a simple 
prediction model, based on the EUS criteria, the univariate OR of individual EUS features 
was converted into a point system (Fig. 2). To validate these EUS criteria, we applied it to 
the validation cohort and compared its performance among both cohorts. The AUC from the 
derivation cohort was 0.92 (Hosmer-Lemeshow goodness-of-fit = X) (Fig. 3A) compared 
with 0.86 (Hosmer-Lemeshow goodness-of-fit = X) in the validation cohort (Fig. 3B). When 
both cohorts were combined, the sensitivity, specificity, and positive predictive value (PPV) 
for a score ≥ 3 in predicting a malignant hepatic mass were 85%, 82%, and 88%, 
respectively (Fig. 3C).
Conclusions
The detection of hepatic metastasis is important for determining prognosis and guiding 
patient care. In a meta-analysis, the sensitivity of CT and TUS in the detection of hepatic 
metastasis was 70% and 66%, respectively.8 The sensitivities are likely lower, given the soft 
criterion standard used in the majority of studies. Smaller lesions are more likely to be 
missed by noninvasive imaging as shown by Kuszyk et al,13 who demonstrated a CT 
sensitivity of 81% for all hepatic masses versus 56% for those < 10 mm. Our findings were 
corroboratory in that radiographically occult hepatic masses identified by EUS only were 
significantly smaller than those also seen by noninvasive imaging, leading to our view that 
EUS is complementary to other imaging modalities in patients undergoing cancer staging. In 
addition, EUS-FNA is an effective technique for tissue acquisition. When compared with our 
strict diagnostic criterion standard, 93.6% of hepatic mass EUS-FNA resulted in a TP or TN 
result. This is similar to prior studies that reported a diagnostic yield of 87% to 94% for 
hepatic EUS-FNA.14–16
Several studies evaluated EUS features that may help distinguish benign from malignant 
hepatic masses. Nguyen et al16 characterized hepatic masses and noted that all malignant 
hepatic masses were round with regular borders and lacked an internal Doppler signal. 
Similarly, another study found that metastatic lesions were more likely to have regular outer 
margins and have additional hepatic masses.14 In this study, there was no significant 
difference in echogenicity and size between malignant and nonmalignant masses. Finally, 
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tenBerge et al17 did not find any EUS characteristics that were predictive of malignancy 
including the size, shape, echogenicity, and border of the lesion.
We were able to derive and validate EUS criteria that may help to distinguish benign from 
malignant hepatic masses with a PPV of 88%. This information may be helpful for guiding 
the decision whether to perform hepatic mass EUS-FNA or not and for selecting the ideal 
lesion when multiple masses are visualized, thereby limiting the number of FNA passes and 
potentially increasing safety. The IOA between 10 expert endosonographers’ assessment of 
the individual EUS criteria ranged from fair to substantial. Most features that were 
eventually incorporated into the diagnostic algorithm with high predictive value for 
malignancy (2 components—echogenicity and distort adjacent structures) had moderate to 
substantial IOA. This range in IOA is similar to EUS studies assessing the presence of 
chronic pancreatitis features,18,19 characteristics of malignant cystic pancreatic lesions,20 
and pancreatic features among familial pancreatic cancer kindreds.21 Beyond EUS, 
endobronchial US in the diagnosis of intrathoracic lymph nodes22 and US in the diagnosis of 
breast cancer23 and thyroid nodules24 also have a wide range of IOA scores. We speculate 
that this range of IOA may be improved through education.
As increasing volumes of hepatic mass FNAs are being performed during EUS, it is 
important to know the risks associated with the procedure. The risk of hepatic EUS-FNA is 
higher than EUS-FNA of other sites, which was confirmed by a meta-analysis that found 
hepatic EUS-FNA had the second highest morbidity rate (2.3%) exceeded only by FNA of 
ascites.25 Six adverse events were reported in a retrospective international questionnaire that 
involved 167 EUS-FNAs (3.6%), including abdominal pain (n = 2), fever (n = 2), bleeding 
(n = 1), and death (n = 1).17 Serious adverse events occurred in 2.9% of our patient cohort, 
which is similar to the rates reported by the meta-analysis.25 Although each of the adverse 
events was clearly related to the EUS examination and/or accompanying ERCP, it is unlikely 
that any of them was directly related to the FNA itself.
The main limitation of this study was the use of only 1 endosonographer to derive and 
validate the EUS criteria on 2 independent cohorts. The decision to limit the number of 
people for the derivation and validation processes was to minimize the variability and 
interobserver differences that would prohibit detection of an adequate statistical signal. In 
addition, even though the images were selected while the endosonographer was blinded to 
all details of the patient medical records and did not know which lesions were benign or 
malignant, one cannot absolutely exclude some memory during subsequent review. A 
potential study limitation is the use of one person and not the expert panel in the validation 
process. This was the suggested approach from our statisticians, given the high interobserver 
variability that was seen with the initial derivation cohort among the expert 
endosonographers. Another limitation of this study was the use of only an individual still 
image rather than a video clip of the hepatic masses. This may have prohibited full 
recognition of the more subtle aspects of the hepatic masses and surrounding hepatic 
parenchyma. Furthermore, clinical data, which is typically incorporated into clinical 
decision making and influences image interpretation, were not provided to the 
endosonographers. However, we thought it necessary to withhold this information to more 
accurately determine the independent performance of EUS in this setting. An additional 
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limitation is the inability of the EUS criteria to capture all features that make a hepatic mass 
appear benign versus malignant. This limitation partly results from the overlapping 
appearance that benign and malignant hepatic masses have. If a lesion did not fulfill the EUS 
criteria for either being clearly benign or malignant, it was considered indeterminate. Also, 
given that the majority of metastases represented adenocarcinoma, and despite the 
comparable diagnostic accuracy for adenocarcinoma versus non-adenocarcinoma tumor 
types, we believe our criteria should be applied solely to patients with suspected 
adenocarcinoma. Additional work is needed to derive and validate EUS criteria that identify 
non-adenocarcinoma hepatic masses. Finally, our study included a select patient population 
in whom study inclusion was based on EUS detection of a hepatic mass. In addition, for the 
patients found to have a mass on prior imaging, the initial imaging provided a clue to the 
endosonographer, thereby aiding EUS detection. An accurate comparison of the 
performance characteristics of EUS-FNA to CT and/or MRI requires prospective evaluation 
within a consecutive patient cohort that includes all comers.
In summary, EUS criteria that distinguish benign from malignant hepatic masses were 
derived and validated. Although higher adverse event rates have been reported, given our 
low adverse event rate, some may favor hepatic FNA regardless of the EUS appearance. The 
data have altered our practice and may impact clinical decision making elsewhere in the 
following manner: (1) The EUS appearance can encourage endosonographers who have had 
reluctance to perform hepatic EUS-FNA to now sample worrisome-appearing hepatic 
masses while feeling more assured about foregoing biopsy for very benign-appearing 
lesions. (2) The EUS appearance can help determine the ideal lesion on which to perform 
FNA. Because patients often have multiple hepatic masses, endosonographers may use the 
EUS appearance to target the most worrisome-appearing lesions to further minimize risk, 
decrease the number of biopsies, and secondarily improve examination efficiency. (3) If a 
lesion appears highly suspicious or very benign based on the criteria, but preliminary in-
room interpretations are nondiagnostic, the appearance would likely encourage additional 
biopsies or limit the number of biopsies, respectively. Further study is needed to determine 
the impact of these EUS criteria among endosonographers of all levels of experience. The 
greatest value of this study may be to highlight (1) the need to carefully examine the liver 
during cancer staging, (2) the ability to detect hepatic masses beyond the left lobe, (3) the 
ability to detect radiographically occult and often diminutive <5 mm masses, (4) the 
apparent safety of FNA in this setting, and (5) the high PPV of the derived and validated 
EUS criteria.
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APPENDIX 1 Indication for EUS
Indication for EUS
Set 1 (n = 100) Set 2 (n = 100)
Cytology (+)* Cytology (−)* Cytology (+)* Cytology (−)*
Pancreatic adenocarcinoma 36 10 34 10
Esophageal adenocarcinoma 6 5 6 6
Colorectal adenocarcinoma 1 1 2 0
Gastric adenocarcinoma 2 2 1 2
Ampullary adenocarcinoma 0 0 1 1
Cholangiocarcinoma/gallbladder cancer 3 2 4 2
Adenocarcinoma of unknown primary site 2 0 1 0
Pancreatic neuroendocrine tumor 5 4 6 4
Hepatocellular carcinoma 1 0 1 0
Melanoma 1 0 0 0
Lymphoma 0 1 0 1
Other (gynecologic, genitourinary cancers) 0 3 0 2
Benign lesions 0 15 0 16
Total 57 43 56 44
*(+) and (−) apply to the EUS-guided FNA cytologic result from the liver mass itself.
APPENDIX 2. DEFINITIONS FOR THE EUS CRITERIA TO DISTINGUISH 
BENIGN FROM MALIGNANT HEPATIC MASSES
Benign criteria
(1) Hyperechoic (distinctly)
Definition: The hepatic mass is distinctly more hyperechoic (brighter) than the surrounding 
hepatic parenchyma.
Notes/clues: Most often represents a benign mass (eg, hemangioma). However, one must 
also consider a neuroendocrine tumor in the proper clinical setting.
(2) Geographic shape (distinctly)
Definition: The hepatic mass has a shape other than round or oval. Can include square, 
rectangular, triangular, more complex shape or described as having a peculiar or vague 
shape.
Notes/clues: This criterion applies to the shape of the entire lesion and does not apply to the 
internal topographic features or the border characteristics.
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Malignant criteria
(1) Two components
Definition: The hepatic mass contains two components, including a central (inner) and 
peripheral (outer) component that differ in echogenicity.
Notes/clues: The outer component may be very thin (about 1–2 mm) and is easy to miss, 
therefore important to examine.
With isoechoic/slightly hyperechoic center
Definition: For hepatic masses with two components, the central (inner) component is 
isoechoic (or only slightly hyperechoic) relative to the surrounding liver parenchyma.
Notes/Clues: When the outer component is hypoechoic, which is usually the case, it can lead 
the interpreter to falsely perceive the central component as being more hyperechoic 
(brighter) than actual. Try to compare the echogenicity of the central component to the liver 
parenchyma and not to the outer component.
Without isoechoic/slightly hyperechoic center
Definition: For hepatic masses with two components, the central (inner) component is either 
hypoechoic or distinctly hyperechoic relative to the surrounding liver parenchyma.
(2) Post-acoustic enhancement
Definition: The hepatic parenchyma located deep to the hepatic mass appears more 
echogenic (brighter) compared with other regions of hepatic parenchyma.
Notes/clues: The presence or absence of post-acoustic enhancement cannot be assessed if 
the mass abuts the deepest aspect of the liver edge (ie, absence of hepatic parenchyma deep 
to the mass). In this situation, the criterion is considered absent.
(3) Distort adjacent structures
Definition: The hepatic mass clearly deforms or alters the shape or course of adjacent 
normal structures (liver border, bile duct, vessels).
Notes/clues: Evaluation of this feature assumes that the mass is in close enough proximity to 
a normal anatomic structure to potentially distort adjacent structures. If not, this criterion is 
considered absent.
Distortion, if present, should be scored as either distinctly or slightly.
If the mass protrudes from the edge of the liver (ie, liver parenchyma is seen on only one 
side of the mass) we score this criterion as being present.
Even if the mass distinctly distorts the liver capsule, if the border of the mass that extends 
beyond the liver is markedly irregular, then this criterion is considered absent.
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(4) Hypoechoic
Definition: The hepatic mass is more hypoechoic (darker) than the surrounding liver 
parenchyma.
Notes/clues: If present, should be scored as either distinctly or slightly. When considering 
whether a mass is hypoechoic, it is important to evaluate the gain setting. Use of too much or 
too little gain alters one’s sense of the relative echogenicity of the mass. For instance, when 
imaging is performed by using too high a gain setting (entire image appears bright), it tends 
to result in an underappreciation of how much darker (hypoechoic) the mass is compared 
with the hepatic parenchyma. Therefore, one may fail to designate the mass as intensely 
hypoechoic.
On the contrary, if the image was obtained with a low gain setting, then the entire image 
appears dark (hypoechoic), often leading to an overestimation of how much darker 
(hypoechoic) the mass is compared with the hepatic parenchyma.
(5) Size ≥ 10 mm
Definition: The hepatic mass is ≥ 10 mm in any axis.
Notes/clues: The markings embedded in the images can be used to estimate the size of the 
mass.
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APPENDIX 3. EXAMPLES OF EACH EUS CRITERION
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Abbreviations
AUC area under the receiver operating characteristic curve
EUS-FNA EUS-guided FNA
IOA interobserver agreement
MRI magnetic resonance imaging
PPV positive predictive value
REDCap research electronic data capture
TP true positive
TN true negative
TUS transabdominal ultrasound
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Figure 1. 
Flow chart of the derivation and validation process. ROC, receiver operating characteristic 
curve; NPV, negative predictive value; PPV, positive predictive value.
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Figure 2. 
Derived and validated EUS criteria that distinguish benign from malignant hepatic masses.
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Figure 3. 
Area under the receiver operator characteristic curve for the derivation and validation of the 
EUS criteria that distinguish benign from malignant hepatic masses. A, Derivation cohort 
AUC. B, Validation cohort AUC. C, Combined AUC for all 200 hepatic masses. AUC, area 
under the curve.
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TABLE 1
Interobserver agreement among expert endosonographers for initial endosonographic characteristics
Initial endosonographic feature Kappa Range
One or 2 components 0.48 0.38–0.58
For entire mass (1 component lesion) or central region (2 component lesions)
 Shape (round, oval, irregular) 0.33 0.26–0.39
 Echogenicity (hyperechoic, hypoechoic, isoechoic) 0.66 0.58–0.73
 Border (regular, irregular) 0.26 0.19–0.34
 Homogeneity (homogeneous, inhomogeneous) 0.33 0.24–0.43
For outer halo in 2 component lesions
 Shape 0.36 0.30–0.44
 Echogenicity relative to the central lesion 0.49 0.39–0.59
 Echogenicity relative to the remainder of the liver 0.48 0.39–0.58
 Border 0.37 0.30–0.45
 Homogeneity 0.39 0.30–0.46
For mass in its entirety
 Cystic component 0.43 0.05–0.72
 Post-acoustic altered echogenicity (shadow, enhancement) 0.30 0.15–0.44
 Deform or distort adjacent structures 0.47 0.37–0.56
For surrounding liver
 Fatty liver 0.22 0.15–0.30
 Cirrhosis 0.32 0.19–0.45
 Professional opinion (benign, malignant) 0.45 0.38–0.53
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TABLE 2
Univariate odds ratio of the derived EUS criteria for predicting malignancy
EUS criterion Odds ratio Range
Hyperechoic (distinctly) 0.10 0.03–0.31
Geographic shape (distinctly) 0.11 0.01–0.95
Two components 3.77 1.80–7.91
Post-acoustic enhancement 11.96 2.62–54.56
Distorts adjacent structures 6.15 2.61–14.51
Hypoechoic 1.74 1.08–2.80
Size ≥10 mm 2.62 1.10–6.24
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